Recombinant SARS-CoV Matrix Protein (aa 182-216) (CAT#: VReP-Wyb029)

CAT Size Price Quantity  
VReP-Wyb029
For Research Use Only. We do not provide direct services or products for patients.

  • Product Overview
  • SARS-CoV, Recombinant Protein, Matrix protein (aa 182-216).
  • Source
  • E. coli
  • Tag
  • None
  • Target
  • SARS-CoV
  • Type
  • Viral Antigens
  • Applications
  • ELISA, WB, SDS-PAGE, Immunogen, etc.
  • Formulation
  • Each vial contains 100 μg of lyophilized protein in 50mM Tris-HCl, 60mM NaCl and 50% glycerol.
  • Purity
  • > 95% pure by SDS-PAGE.
  • Product Form
  • Powder
  • Storage
  • Store at 2 °C to 8 °C short term, -20 °C long term.
  • Introduction
  • A novel coronavirus has been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive stranded RNA approximately 27 to 31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2.
  • Alternative Names
  • E2; E2 glycoprotein; Peplomer protein; S; S glycoprotein; Severe acute respiratory syndrome spike glycoprotein; Severe acute respiratory syndrome virus spike glycoprotein; Spike glycoprotein; VGL2; SARS-CoV; Coronavirus (SARS assoc) Spike; Coronavirus SAR

Related products


Online Inquiry For Research Use Only. We do not provide direct services or products for patients.


Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.




Inquiry

Top
Inquiry Basket